

# silenceworks

BENITEC'S PROGRESS IN SILENCE

## Market Snapshot

### Market Data as at November 5, 2014

ASX Code:	BLT
OTC Code:	BTEBY
Market Cap:	AUD 69,131,39652
52 Week High/low:	AUD 2.38-0.45
Shares on Issue:	115,218,993
Industry Sector:	Pharmaceuticals, Biotechnology & Life Sciences

### In this issue

- ▶ TT-034: Update of hepatitis C clinical trial
- ▶ Gilead's Harvoni: Why focus on hepatitis C is a plus for Benitec
- ▶ AGM and Shareholder Information Sessions and Webcast
- ▶ Benitec presents in the ASX Investor Series
- ▶ Benitec dedicates new US 'Bremner Lab' to key investor
- ▶ Benitec licences ddRNAi for intractable pain to Circuit Therapeutics
- ▶ Benitec in The Monthly, Sky Business News and The Scientist
- ▶ Benitec launches app for 'one touch' access to ASX info.

## ANNUAL GENERAL MEETING 2014


### + Shareholder Information Sessions in Sydney (with Webcast) & New York

[Details >](#)



### TT-034: Update of hepatitis C clinical trial

On November 3, 2014, Benitec's CEO and MD, Dr Peter French gave a detailed update [BoardRoom Radio](#). Discover how strict inclusion and exclusion criteria, designed to ensure patient safety and drug efficacy in this first in man trial, have contributed to a delay in patient dosing. Hear about the steps being taken to increase the rate of trial recruitment, with two more trial sites expected to be operating in January. Learn how TT-034's liver delivery was demonstrated in the first patient, and why strict selection criteria are likely to be relaxed once the drug's safety profile has been established in the first trial. [More>](#)



### Gilead's Harvoni: Why focus on hepatitis C is a plus for Benitec

After Gilead recently announced FDA approval for Harvoni, its one-a-day tablet for hepatitis C, Benitec's head of R&D, Dr David Suhy explains why highlighting hepatitis C is a plus for Benitec. Find out how Harvoni works, what it costs, and the impact for insurers and payers. Learn why cost, patient compliance and re-infection rates underscore the advantages of a ddRNAi-based approach. [More>](#)



### AGM, Shareholder Information Sessions and Webcast

Benitec's AGM will be held in Sydney on November 13, 2014, followed by an Information Session, where shareholders can ask questions, and meet the board, management team and other shareholders. The session will be webcast for those unable to attend, and a separate Shareholder Information Session will be held in New York on November 19, 2014. More details in [AGM and Shareholder Information Sessions](#) and the [2014 Annual Report](#).



### Benitec presents in the ASX Investor Series

On October 16, 2014, Benitec was presented as part of the ASX Investor Series. Watch the [Finance News Network](#) video and learn why Benitec's CBO Carl Stubbings describes ddRNAi as 'exquisite', see the comparison with RNAi companies Arrowhead and Alnylam, and learn why Benitec has significant 'headroom for growth'.




### Benitec dedicates new US 'Bremner Laboratory' to key investor

In September, Benitec opened a new laboratory facility in the Bay Area of San Francisco, California. Dedicated to seminal and long term investor, Dr Christopher Bremner, the laboratory markedly expands Benitec's research and development capacity. Senior VP of R&D Dr David Suhy heads up the new lab, joined by the team behind development of TT-034, Benitec's lead therapeutic.



### Benitec licences ddRNAi for pain to Circuit Therapeutics

In early November, Benitec executed an exclusive license with Circuit Therapeutics for use of ddRNAi to treat intractable pain. This is severe, constant pain which is not curable with current therapies. Circuit plans to use ddRNAi to block Nav1.7, a sodium channel critical for pain generation, thereby controlling pain without the side-effects of less specific therapies. [More>](#)



### Benitec in The Monthly, Sky Business and The Scientist and more

'[Dr Graham's Patented Elixir: the course of true discovery never did run smooth](#)' is the title of this insightful and detailed article in The Monthly. Learn why Benitec's CBO Carl Stubbings talks about 'best in market' not 'first in market' in this informative [Sky Business News](#) interview. In its article '[The Second coming of RNAi](#)' read how The Scientist believes that, 16 after discovery, RNAi is starting to fulfil its promise.



### Benitec launches app for 'one touch' access to ASX info

In October, Benitec launched an app that gives instant, mobile access to the latest company information – such as share price, ASX announcements and corporate presentations. This free app is available from the Apple App store and Google Play (just type in Benitec) and enables quick, one touch access to key financial data at any time, wherever you are. [More>](#)